Nuclear farnesoid X receptor protects against bone loss by driving osteoblast differentiation through stabilizing RUNX2

Abstract

The delicate balance between bone formation by osteoblasts and bone resorption by osteoclasts maintains bone homeostasis. Nuclear receptors (NRs) are now understood to be crucial in bone physiology and pathology. However, the function of the Farnesoid X receptor (FXR), a member of the NR family, in regulating bone homeostasis remains incompletely understood. In this study, in vitro and in vivo models revealed delayed bone development and an osteoporosis phenotype in mice lacking FXR in bone marrow mesenchymal stem cells (BMSCs) and osteoblasts due to impaired osteoblast differentiation. Mechanistically, FXR could stabilize RUNX2 by inhibiting Thoc6-mediated ubiquitination, thereby promoting osteogenic activity in BMSCs. Moreover, activated FXR could directly bind to the Thoc6 promoter, suppressing its expression. The interaction between RUNX2 and Thoc6 was mediated by the Runt domain of RUNX2 and the WD repeat of Thoc6. Additionally, Obeticholic acid (OCA), an orally available FXR agonist, could ameliorate bone loss in an ovariectomy (OVX)-induced osteoporotic mouse model. Taken together, our findings suggest that FXR plays pivotal roles in osteoblast differentiation by regulating RUNX2 stability and that targeting FXR may be a promising therapeutic approach for osteoporosis.

References

[1.] Feng X, McDonald JM. Disorders of bone remodeling. Annu. Rev. Pathol., 2011, 6: 121-145.

[2.] Jacome-Galarza CE, et al.. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature, 2019, 568: 541-545.

[3.] Logan M, et al.. Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis, 2002, 33: 77-80.

[4.] Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet, 2011, 377: 1276-1287.

[5.] Margolis RN. Nuclear receptors and bone. Ann. N. Y Acad. Sci., 2007, 1116: 327-334.

[6.] Imai Y, et al.. Nuclear receptors in bone physiology and diseases. Physiol. Rev., 2013, 93: 481-523.

[7.] Shapiro H, et al.. Bile acids in glucose metabolism in health and disease. J. Exp. Med., 2018, 215: 383-396.

[8.] Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat. Rev. Gastroenterol. Hepatol., 2021, 18: 335-347.

[9.] Cho SW, et al.. Positive regulation of osteogenesis by bile acid through FXR. J. Bone Min. Res., 2013, 28: 2109-2121.

[10.] Id BH, et al.. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone, 2011, 49: 1219-1231.

[11.] Komori T, et al.. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 1997, 89: 755-764.

[12.] Mundlos S, et al.. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell, 1997, 89: 773-779.

[13.] Otto F, et al.. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 1997, 89: 765-771.

[14.] Kim JM, et al.. A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nat. Commun., 2020, 11. 2289

[15.] Shen R, et al.. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J. Biol. Chem., 2006, 281: 16347-16353.

[16.] Jones DC, et al.. Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science, 2006, 312: 1223-1227.

[17.] Zhao M, et al.. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J. Biol. Chem., 2003, 278: 27939-27944.

[18.] Thacker G, et al.. Skp2 inhibits osteogenesis by promoting ubiquitin-proteasome degradation of Runx2. Biochim. Biophys. Acta, 2016, 1863: 510-519.

[19.] Zhu W, et al.. The E3 ubiquitin ligase WWP2 facilitates RUNX2 protein transactivation in a mono-ubiquitination manner during osteogenic differentiation. J. Biol. Chem., 2017, 292: 11178-11188.

[20.] Jun JH, et al.. BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J. Biol. Chem., 2010, 285: 36410-36419.

[21.] Kim BG, et al.. Runx2 phosphorylation induced by fibroblast growth factor-2/protein kinase C pathways. Proteomics, 2006, 6: 1166-1174.

[22.] Bae HS, et al.. An HDAC inhibitor, Entinostat/MS-275, partially prevents delayed cranial suture closure in heterozygous Runx2 Null mice. J. Bone Miner. Res., 2017, 32: 951-961.

[23.] Jeon EJ, et al.. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J. Biol. Chem., 2006, 281: 16502-16511.

[24.] Suo J, et al.. VGLL4 promotes osteoblast differentiation by antagonizing TEADs-inhibited Runx2 transcription. Sci. Adv., 2020, 6: eaba4147.

[25.] Liu Z, et al.. Mediator MED23 cooperates with RUNX2 to drive osteoblast differentiation and bone development. Nat. Commun., 2016, 7. 11149

[26.] Han Y, et al.. Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation. J. Clin. Invest., 2019, 129: 1895-1909.

[27.] Liu Y, et al.. Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-beta signaling pathway. Proc. Natl. Acad. Sci. USA, 2021, 118: e2111401118.

[28.] Artigas N, et al.. p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation. Cell Death Differ., 2017, 24: 2022-2031.

[29.] Collins GA, Goldberg AL. The logic of the 26S proteasome. Cell, 2017, 169: 792-806.

[30.] Wang X, et al.. UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase/deubiquitinase-substrate interactions in eukaryotic species. Nucleic Acids Res., 2022, 50: D719-D728.

[31.] Li Y, et al.. An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat. Commun., 2017, 8. 347

[32.] Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases(dagger). J. Hepatol., 2023, 78: 430-441.

[33.] Mayo MJ. Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis?. Hepatology, 2022, 76: 518-531.

[34.] Neuschwander-Tetri BA, et al.. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, 2015, 385: 956-965.

[35.] Xu S, et al.. Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation. Kidney Int., 2022, 101: 987-1002.

[36.] Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs, 2016, 76: 1221-1226.

[37.] Khalid AB, Krum SA. Estrogen receptors alpha and beta in bone. Bone, 2016, 87: 130-135.

[38.] Zarei A, et al.. Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts. Bone Res., 2016, 4: 16030.

[39.] Xu Z, et al.. SMURF2 regulates bone homeostasis by disrupting SMAD3 interaction with vitamin D receptor in osteoblasts. Nat. Commun., 2017, 8. 14570

[40.] Cho SW, et al.. Osteoblast-targeted overexpression of PPARgamma inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice. J. Bone Miner. Res., 2011, 26: 1939-1952.

[41.] Goel D, Vohora D. Liver X receptors and skeleton: current state-of-knowledge. Bone, 2021, 144: 115807.

[42.] Li X, et al.. Targeting actin-bundling protein L-plastin as an anabolic therapy for bone loss. Sci. Adv., 2020, 6: eabb7135.

[43.] Katahira J. mRNA export and the TREX complex. Biochim. Biophys. Acta, 2012, 1819: 507-513.

[44.] Ruaud L, et al.. Biallelic THOC6 pathogenic variants: prenatal phenotype and review of the literature. Birth Defects Res., 2022, 114: 499-504.

[45.] Accogli A, et al.. Novel CNS malformations and skeletal anomalies in a patient with Beaulieu-boycott-Innes syndrome. Am. J. Med. Genet. A, 2018, 176: 2835-2840.

[46.] Schapira M, et al.. WD40 repeat domain proteins: a novel target class?. Nat. Rev. Drug Discov., 2017, 16: 773-786.

[47.] Pashkova N, et al.. WD40 repeat propellers define a ubiquitin-binding domain that regulates turnover of F box proteins. Mol. Cell, 2010, 40: 433-443.

[48.] Jackson S, Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem. Sci., 2009, 34: 562-570.

[49.] Dubiel W, et al.. Cullin 3-based ubiquitin ligases as master regulators of mammalian cell differentiation. Trends Biochem. Sci., 2018, 43: 95-107.

[50.] Lee J, Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol. Cell, 2007, 26: 775-780.

[51.] Higa LA, et al.. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat. Cell Biol., 2006, 8: 1277-1283.

[52.] Biedermann S, Hellmann H. WD40 and CUL4-based E3 ligases: lubricating all aspects of life. Trends Plant Sci., 2011, 16: 38-46.

[53.] Snyder S. Postmenopausal osteoporosis. N. Engl. J. Med., 2024, 390: 675-676

[54.] Reid IR. A broader strategy for osteoporosis interventions. Nat. Rev. Endocrinol., 2020, 16: 333-339.

[55.] Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet, 2022, 399: 1080-1092.

[56.] Davis S, et al.. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol. Assess., 2020, 24: 1-314.

[57.] Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. Lancet, 2019, 394: 2131-2133.

[58.] Musso G, Cassader M, Gambino R. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet, 2015, 386: 27.

[59.] Vachliotis ID, et al.. Nonalcoholic fatty liver disease and osteoporosis: a potential association with therapeutic implications. Diabetes Obes. Metab., 2022, 24: 1702-1720.

[60.] Danford CJ, et al.. The pharmacologic management of osteoporosis in primary biliary cholangitis: a systematic review and meta-analysis. J. Clin. Densitom., 2020, 23: 223-236.

[61.] Zhang H, et al.. Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression. Sci. Adv., 2023, 9: eabo7868.

[62.] Roman-Blas JA, Herrero-Beaumont G. Targeting subchondral bone in osteoporotic osteoarthritis. Arthritis Res. Ther., 2014, 16: 494.

[63.] Bellido M, et al.. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthr. Cartil., 2011, 19: 1228-1236.

[64.] Chen Q, et al.. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?. Cell Death Differ., 2016, 23: 1128-1139.

[65.] Hendrickx G, et al.. Piezo1 inactivation in chondrocytes impairs trabecular bone formation. J. Bone Miner. Res., 2021, 36: 369-384.

[66.] Yan Y, et al.. The HDOCK server for integrated protein-protein docking. Nat. Protoc., 2020, 15: 1829-1852.